HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; BMI, body mass index; FAS, full analysis set; LS, least squares; SD, standard deviation; CI, confidence interval; TC, total cholesterol; LD
1. Primary Endpoints * Biomarker data suggestive of regorafenib-mediated inhibition of the RAS-RAF- MEK-ERK signal transduction pathway,of various tyrosine kinase receptors and/or of angiogenesis. *
Objectives: To evaluate the impact of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on the inflammatory response and viral clearance in coronavirus disease 2